Poland· PL-100309540
Edarbi
A azilsartan medoxomil product containing azilsartanum medoxomilum, registered in Poland by Takeda Pharma A/S. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Azilsartan medoxomil is registered in 10 of 19 countries.
Countries holding a registration under ATC C09CA09 (azilsartan medoxomil), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Azilsartan medoxomil · ATC C09CA09
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of azilsartan medoxomil costs, country by country.
Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Azilsartan medoxomil · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.47
The record
At a glance
URPL (Poland)- Active substance
- Azilsartanum medoxomilum
- Manufacturer
- Takeda Pharma A/S
- Country
- Poland (PL)
- ATC code
- C09CA09
- ATC class
- Azilsartan medoxomil
- Defined daily dose
- 40 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
170 interactions on record for azilsartan medoxomil.
Graded by severity as the source publishes them — 7 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Azilsartan medoxomil · interactions on record
170 records
- 7 severe
- 118 moderate
Most severe, free to view
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- Potassium gluconateA12BA05severe
- Potassium chlorideB05XA01severe
45 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Azilsartan medoxomil in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0c2f9891-3111-4def-a1ad-d2feba281b61 GET /v1/drugs/0c2f9891-3111-4def-a1ad-d2feba281b61?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki",
"source": "urpl",
"strength": "20 mg",
"packaging": "Rp ¦ EU/1/11/734/001 ¦ 88805\n14 tabl.\nRp ¦ EU/1/11/734/002 ¦ 88806\n28 tabl.\nRp ¦ EU/1/11/734/003 ¦ 88807\n56 tabl.\nRp ¦ EU/1/11/734/004 ¦ 88808\n98 tabl.\nRp ¦ EU/1/11/734/012 ¦ 88809\n30 tabl.\nRp ¦ EU/1/11/734/013 ¦ 88810\n90 tabl.\nRp ¦ EU/1/11/734/019 ¦ 131564\n14 tabl.\nRp ¦ EU/1/11/734/020 ¦ 131565\n28 tabl.\nRp ¦ EU/1/11/734/021 ¦ 131566\n56 tabl.\nRp ¦ EU/1/11/734/022 ¦ 131567\n98 tabl.",
"substance": "Azilsartanum medoxomilum 20 mg",
"common_name": "Azilsartanum medoxomilum",
"pl_product_id": "100309540",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about azilsartan medoxomil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.